Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit

Vertex Pharmaceuticals deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950 underscore the significant potential for HCV protease inhibitors to alter the landscape of disease treatment and suggests pharmaceutical dealmakers will have to be ever more flexible to land biotech's best products.

Just how flexible does a Big Pharma have to be to win an important new drug? Practically contortionary.

Vertex Pharmaceuticals Inc. 's deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo